Regenxbio

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Super Micro Computer, Bakkt Holdings, MARA Holdings, Microstrategy, And Tesla Inc: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CHWY

HUMA

NYXH

ORKA

PPTA

RAPP

RGNX

ZYBT

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Pharmaceutics,Laboratory:,Pipette,Dropping,Yellow,Liquid,Into,Test,Tubes,,Medical

Biotech

Health Care

Regenxbio&#39;s RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and a well-tolerated safety profile.

Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial

Coppell,,Tx,,Usa,-,March,19,,2022:,Signet,Jewelers,Company

AFRM

EXOD

LCID

LZMH

OLLI

PAGS

ROKU

STNE

Signet Jewelers, BGM Group, StoneCo, Ollie&#39;s Bargain Outlet And Other Big Stocks Moving Higher On Wednesday

Regenxbio Inc

Press Releases

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Earnings

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

ABBV

AMTM

KELYA

QRVO

SPGI

TRNO

WDAY

Absci

Abivax

Celcuity

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Cogent Biosciences

Erasca

Kura Oncology

MeiraGTx Hldgs

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Oruka Therapeutics

Precigen

Prothena Corporation plc - Ordinary Shares

Prothena Corp

PureTech Health plc - American Depositary Shares

PureTech Health

Relay Therapeutics

Sage Therapeutics

Sana Biotechnology

Sionna Therapeutics

Stoke Therapeutics

Savara

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tourmaline Bio

Tyra Biosciences

Upstream Bio

Verve Therapeutics

Verastem

Goldman Sachs

HC Wainwright & Co.

Chardan Capital

Morgan Stanley

Comments

Regenxbio

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell